PubRank

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Clinical Trial ID NCT00859781

PubWeight™ 16.39‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00859781

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010 2.28
2 Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 2013 1.51
3 Unconventional nuclides for radiopharmaceuticals. Mol Imaging 2010 1.23
4 Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals. Dalton Trans 2011 1.11
5 Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy. Adv Urol 2012 1.07
6 Current status of immunological therapies for prostate cancer. Curr Opin Urol 2010 1.06
7 Prostate-specific membrane antigen-based therapeutics. Adv Urol 2011 1.06
8 Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol 2012 0.92
9 Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014 0.90
10 Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother 2010 0.86
11 Recent developments in prostate cancer biomarker research: therapeutic implications. Br J Clin Pharmacol 2011 0.86
12 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
13 Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol 2012 0.81
14 New drugs in prostate cancer. Prostate Int 2016 0.80
15 Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol 2012 0.77
16 Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancer. Am J Nucl Med Mol Imaging 2014 0.75
Next 100